Translate
Axsome Therapeutics, Inc.
About
Axsome Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 1 2026
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
Apr 30 2026
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
Apr 8 2026
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
Apr 1 2026
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Recent Videos
LIVE: Axsome First Quarter 2026 Financial Results
May 05, 2026
Axsome Therapeutics AUVELITY® FDA Approval Investor Event | May 01, 2026
May 03, 2026
Auvelity receives FDA approval for dementia in Alzheimer's Disease
May 01, 2026
Axsome Therapeutics (AXSM) Stock Analysis 2026: Financial Health, Valuation & Performance Breakdown
May 01, 2026